The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
In silico tumor immune microenvironment (TiME) analysis of non-small cell lung cancer (NSCLC) to inform clinical development of CDR404: A first-of-its-kind MAGE-A4 targeted T-cell engager.
 
Daniel Lenherr-Frey
Employment - CDR-Life
Stock and Other Ownership Interests - CDR-Life; Novartis
 
Melissa Vrohlings
Employment - CDR-Life
Stock and Other Ownership Interests - CDR-Life; Virometix
 
Maria Bouvy-Liivrand
No Relationships to Disclose
 
Reija Hieta
No Relationships to Disclose
 
Heather May Shaw
Consulting or Advisory Role - Bristol-Myers Squibb; CDR-Life; Genzyme; Mallinckrodt/Therakos; MSD Oncology; Novartis; Regeneron; Scancell Ltd.
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Novartis; Sanofi
Research Funding - Agenus (Inst); AstraZeneca/MedImmune (Inst); Genmab (Inst); IDEAYA Biosciences (Inst); Idera (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst); Scancell Ltd. (Inst)
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Agenus; Bristol-Myers Squibb; Merck Sharp & Dohme; Regeneron
(OPTIONAL) Uncompensated Relationships - iOnctura
 
Gilberto Lopes
Stock and Other Ownership Interests - Biomab; CDR-Life; Lucence Diagnostics; Morphometrix; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Janssen; Merck
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
Other Relationship - Mirati Therapeutics
 
Leonardo Borras
Employment - CDR-Life
Leadership - CDR-Life
Stock and Other Ownership Interests - CDR-Life
 
Swethajit Biswas
Employment - Adaptimmune; CDR-Life
Leadership - CDR-Life
Stock and Other Ownership Interests - CDR-Life